Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 7/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23579175 | 1.00 | EPAS1 (0.34) | EPAS1CSNK2A1L3MBTL1PDE4APDE4C | |
| SCHEMBL30848845 | 1.00 | EPAS1 (0.34) | EPAS1CSNK2A1L3MBTL1PDE4APDE4C | |
| SCHEMBL29206714 | 0.82 | CSNK2A1 (0.35) | EPAS1CSNK2A1ALPL | |
| SCHEMBL29959365 | 0.80 | CSNK2A1 (0.32) | CSNK2A1PDE4APDE4CPDE4D | |
| SCHEMBL23578707 | 0.80 | CSNK2A1 (0.32) | CSNK2A1PDE4APDE4CPDE4D | |
| SCHEMBL2185158 | 0.77 | PDE4A (0.34) | PDE4APDE4CPDE4DESR2CA1 | |
| SCHEMBL24819988 | 0.77 | L3MBTL1 (0.34) | CSNK2A1L3MBTL1 | |
| SCHEMBL23592754 | 0.74 | NQO1 (0.39) | CSNK2A1 | |
| SCHEMBL21313423 | 0.74 | PKM (0.43) | EPAS1L3MBTL1ESR2CA1CA2 | |
| SCHEMBL1396954 | 0.74 | PDE4A (0.36) | EPAS1L3MBTL1PDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022271612-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271630-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271749-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |